CagriSema_Dosage, benefits & legal status
Also known as cagrilintide and semaglutide, Cagrilintide + Semaglutide, Semaglutide + Cagrilintide, cagri sema, CagriSema blend
A weekly two-in-one shot combining cagrilintide and semaglutide for bigger loss.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is CagriSema?
Plain language first. The technical label stays, but it never stands alone.Overview
It hits two separate fullness pathways at once for bigger weight loss than either alone. It is still experimental.
CagriSema is a fixed combination of cagrilintide (an amylin copy) and semaglutide (a GLP-1 copy) in one weekly shot.
What it's used for
A weekly two-in-one shot combining an appetite-lowering peptide with semaglutide, for bigger weight loss than either alone.
How does CagriSema work?
What it does in the body, and where.CagriSema is two drugs in one weekly injection: cagrilintide and semaglutide, at fixed doses. The logic is that two separate fullness pathways should add up.
- 01Semaglutide handles the GLP-1 sideAppetite, stomach emptying, blood sugar.
- 02Cagrilintide handles the amylin sideA different route to fullness, so the two do not compete for the same receptor.
- 03Fixed doses, titrated togetherBoth components rise on one schedule over roughly 16 weeks, so you cannot adjust one without the other.
- 04Filed with the FDA, not approvedThe application went in during December 2025. Until a decision, this remains investigational.
Hits 2 receptors at once.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Weight loss, combining two different fullness signalsInvestigational
- Type 2 diabetesInvestigational
The published record
112
Records indexed for CagriSema
79 in humans, 21 of them original studies.
32 registered trials, 1 with posted results.
Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 11 September 2026.
At a glance
Four things to know about CagriSema
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
10 mg
Half-life
6 to 8 days for both parts
How much, and do you cycle it?
The range, and whether you take breaks.2.4 mg per week, weekly. Not cycled in the trialsTrial dose
Given continuously for the whole study period: REDEFINE 1, 68 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.
How long does it stay in the body?
The half-life, and where the figure comes from.6 to 8 days for both partsTrial protocol
Cagrilintide and semaglutide in one injection. Measured together in the same trial, cagrilintide runs about 159 to 195 hours and semaglutide about 145 to 165. They happen to be close, which is why weekly dosing works for the pair.
Source: Lau DCW, et al. PMID 33894838
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Unlike the community blends, this ratio is not a vendor choice. CagriSema is a fixed 1:1 co-formulation and the trials that produced its results used 2.4 mg of each. Research-market vials are usually labelled 5/5 or 10/10, which describes the vial rather than a dose. Read the per-component milligrams off your label, because a vial marked 10 mg total holds 5 mg of each.
Pick your vial to see concentrations and a draw.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
Your draw
CagriSema starts at $64.00 across 3 vendors.
3 listings, last read Sep 4, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized CagriSema keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- A personal or family history of medullary thyroid cancer, or MEN 2
- Pregnancy
Stop and get help
- Severe stomach pain that spreads to your back
- A lump or swelling in your neck, hoarseness, or trouble swallowing
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Stomach effects hit about 80% of people in trials, against 40% on placebo
- Nausea in roughly 55%, constipation 31%, vomiting 26%
- About 6% stopped because of side effects
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is CagriSema approved?
And where the numbers on this page come from.No. CagriSema is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- CheckedSeptember 2026
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
- Reviewed8 September 2026
What else is like CagriSema?
Others in Amylin analogs, side by side.If you're weighing CagriSema, it's worth reading Petrelintide, Eloralintide, and Cagrilintide in the same class.
A weekly two-in-one shot combining cagrilintide and semaglutide for bigger loss.
- Dose
- 2.4 mg per week
- How often
- Weekly
An experimental weekly fullness-hormone shot for weight loss.
- Dose
- 0.6 up to 9 mg per week (start low, increase slowly)
- How often
- Weekly
An experimental weekly fullness-hormone shot for weight loss.
- Dose
- 1 up to 9 mg per week (trial doses)
- How often
- Weekly
A weekly fullness-hormone shot, often paired with semaglutide for bigger loss.
- Dose
- 0.3 up to 4.5 mg per dose (start low, increase slowly)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Novo Nordisk, REDEFINE 1 results published in the New England Journal of Medicine(2025)22.7 percent weight loss at 68 weeks on the adherence estimand versus 2.3 percent placebo. Regardless of adherence the figure was 20.4 percent versus 3.0 percent, difference 17.3 percentage points (95 percent CI -18.1 to -16.6, p<0.001).
- ClinicalTrials.gov NCT05567796, REDEFINE 1(2025)Double-blind, placebo and active controlled, 3,417 adults with obesity or overweight plus a comorbidity, without type 2 diabetes. Gastrointestinal adverse events were reported in 79.6 percent on CagriSema against 39.9 percent on placebo.
Last reviewed 8 September 2026
Beyond these, 112 records are indexed. Browse the records